Drug news
NICE recommends Eylea (Bayer HealthCare) for wet Age-related Macular Degeneration
NICE has announced in draft final guidance that Eylea (aflibercept), from Bayer HealthCare, should be recommended for the treatment of patients with wet Age-related Macular Degeneration (wAMD). It s the first new medicine in ophthalmology to be fast tracked to draft Final Appraisal Determination without the need for additional consultation.
Final guidance is likely to be published in July 2013. The Scottish Medicines Consortium accepted Eylea for use within NHS Scotland for the treatment of wAMD in April 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.